These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26232000)

  • 1. Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
    Gianotti N; Poli A; Nozza S; Spagnuolo V; Tambussi G; Bossolasco S; Cinque P; Maillard M; Cernuschi M; Galli L; Lazzarin A; Castagna A
    J Int AIDS Soc; 2015; 18(1):20037. PubMed ID: 26232000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
    Charpentier C; Lê MP; Joly V; Visseaux B; Lariven S; Phung B; Yéni P; Yazdanpanah Y; Descamps D; Peytavin G; Landman R
    PLoS One; 2015; 10(7):e0134430. PubMed ID: 26226257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
    Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
    Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir.
    Gagliardini R; Bandera A; Zaccarelli M; Sterrantino G; Latini A; D'Avino A; Lapadula G; Antinori A; Cauda R; De Luca A; Gori A; Di Giambenedetto S; Fabbiani M
    Antivir Ther; 2018; 23(2):139-148. PubMed ID: 28799920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
    BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India.
    Dravid A; Betha TP; Sharma AK; Gawali R; Mahajan U; Kulkarni M; Saraf C; Kore S; Dravid M; Rathod N
    HIV Med; 2020 Oct; 21(9):578-587. PubMed ID: 33021066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
    Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
    PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
    Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
    J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.